Upregulated interleukin-6 expression contributes to erlotinib resistance in head and neck squamous cell carcinoma

Area of Science:

• Oncology
• Molecular Biology
• Immunology

Background:

• Epidermal growth factor receptor (EGFR) signaling is crucial in head and neck squamous cell carcinoma (HNSCC).
• Clinical trials of EGFR tyrosine kinase inhibitors (TKIs) show limited efficacy in HNSCC patients.
• Mechanisms of acquired resistance to EGFR TKIs in HNSCC remain incompletely understood.

Purpose of the Study:

• To investigate mechanisms of acquired resistance to the EGFR TKI erlotinib in HNSCC.
• To identify molecular pathways and biomarkers associated with erlotinib resistance.
• To evaluate the therapeutic potential of targeting identified resistance pathways.

Main Methods:

• Development of erlotinib-resistant HNSCC cell lines.
• Microarray analysis of gene expression profiles in resistant versus sensitive cells.
• Pathway and network analyses to identify dysregulated biological processes.
• Validation of key gene expression changes using RT-PCR and ELISA.
• In vivo efficacy studies of IL-6 blockade in resistant HNSCC models.

Main Results:

• Erlotinib-resistant HNSCC cells exhibited significant upregulation of immune response and inflammatory pathways.
• Interleukin-6 (IL-6) was consistently overexpressed in all resistant cell lines.
• IL-6 receptor antagonist tocilizumab effectively overcame erlotinib resistance in vivo.
• Elevated IL-6 expression is a hallmark of erlotinib-resistant HNSCC.

Conclusions:

• Acquired resistance to erlotinib in HNSCC is associated with activation of IL-6 signaling.
• Targeting the IL-6 pathway with agents like tocilizumab may re-sensitize HNSCC to EGFR TKIs.
• IL-6 blockade represents a promising therapeutic strategy to overcome erlotinib resistance in HNSCC.